P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage

• Published in: Cell cycle (Georgetown, Tex.) Vol. 17; no. 17; pp. 2175 - 2186
• Main Authors: Lin, Ru-Wei, Ho, Cheng-Jung, Chen, Hsin-Wen, Pao, Yu-Hsuan, Chen, Li-En, Yang, Min-Chi, Huang, Shih-Bo, Wang, Shiaw, Chen, Chung-Hwan, Wang, Chihuei
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02.09.2018
• Subjects: apoptosis; Apoptosis - drug effects; bcl-2-Associated X Protein - metabolism; Cell Line, Tumor; DNA Damage; DNA replication; Doxorubicin; Doxorubicin - pharmacology; Humans; Male; Postate cancer; Prostatic Neoplasms - metabolism; Proto-Oncogene Proteins c-bcl-2 - metabolism; Research Paper; Signal Transduction - drug effects; Tumor Suppressor Protein p53 - metabolism; apoptosis; DNA replication; Postate cancer; Doxorubicin; DNA damage; p53
• ISSN: 1538-4101; 1551-4005
• DOI: 10.1080/15384101.2018.1520565

We previously demonstrated that Bim is the main BH3-only protein replacing Bak/Bax from Bcl-xl to activate apoptosis in a p53-independent manner in response to doxorubicin in prostate cancer. However, the comparison of doxorubicin treatment between LNCaP cells carrying p53-wild type and PC3 cells carrying p53-null suggested that p53 might be essential for maximizing apoptosis. Inhibition of ATM did not affect doxorubicin-induced apoptosis. Overexpression of p53 did not affect ABT-263-induced apoptosis and nevertheless, the combination of doxorubicin with ABT-263 induced higher apoptotic responses than did doxorubicin or ABT-263 alone. These results advocated that doxorubicin-induced DNA damage controls p53 function for intensifying apoptosis. Indeed, overexpression of p53 only enhanced apoptosis under conditions of severe DNA damage induced by high concentrations of doxorubicin in LNCaP cells. Immunofluorescence staining showed vague γH2AX foci and enlarged nuclei in LNCaP cells in response to high concentrations of doxorubicin, en route to apoptosis. In addition, our results revealed that the apoptosis in response to DNA replication stress induced by CFS-1686, a catalytic inhibitor of topoisomerase, is p53-independent. Interestingly, the combination of doxorubicin with CFS-1686 generated DNA damage and replication stress simultaneously, resulting in a synergistic apoptotic effect in prostate cancer cells. Thus, we concluded that p53 is a sensor for enhanced apoptosis in response to DNA damage stress, not DNA replication stress, at least in prostate cancer.